Canurta Therapeutics, a biotechnology company focused on the development of novel botanical therapeutics for neurodegenerative and inflammatory diseases, is pleased to announce that it has entered into a definitive securities purchase and exchange agreement with PharmaDrug Inc. regarding the acquisition of up to 40% of Canurta’s issued and outstanding limited partnership units.

Definitive Agreement Signed with PHRX: Canurta Advances Public Market Strategy Canurta Therapeutics has signed a Definitive Agreement with PharmaDrug Inc. (CSE: PHRX.CN), formalizing the terms of the proposed acquisition of up to 40 percent of Canurta. This agreement marks a key step forward in Canurta’s strategy to access the public markets, building on the previously announced LOI and reinforcing its focus on long-term growth and capital efficiency. The partnership is designed to support...

In August 2025, Canurta launched the Satoshi Trials to integrate Bitcoin into its treasury model, achieved a key blood-brain barrier milestone for CNR-401, signed a public market LOI with PharmaDrug, and CEO Akeem Gardner spoke on innovation at CanadianSME and the Black Blockchain Summit.